HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
Update: 2025-11-18
Description
touchEXPERT FOCUS for touchONCOLOGY
Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA.
The experts
- Prof. Thomas Seufferlein, Ulm University, Ulm, Germany
- Dr Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- Prof. Florian Lordick, University of Leipzig, Leipzig, Germany
- Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium
This touchPODCAST is for HCPs outside of the UK
This activity is supported by an independent educational grant from Jazz Pharmaceuticals.
Jointly provided by Partners for Advancing Clinical Education and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
